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Background: Cushing’s disease is a rare endocrine disorder characterised by 
cortisol overproduction, with severe complications. Therapies for cortisol reduction 
are often necessary. Outcomes from the pivotal Phase III study of osilodrostat (new, 
potent oral 11β-hydroxylase inhibitor) in Cushing’s disease patients (LINC 3; 
NCT02180217) are reported. 
 
Methods: LINC 3 (prospective, multicentre study) comprised four periods. Cushing’s 
disease patients with mean urinary free cortisol (mUFC)>1·5xULN were enrolled. 
Period 1: open-label osilodrostat was initiated and adjusted every 2 weeks (1–30mg 
twice daily) based on mUFC and safety until week (W)12. Period 2 (W13–24): 
osilodrostat was continued at the therapeutic dose determined during period 1. 
Period 3 (W26): 71 eligible participants (mUFC≤ULN at W24 without up-titration after 
W12) were randomised (1:1 via interactive-response technology; double blind, 
stratified by osilodrostat dose at W24 and history of pituitary irradiation) to continue 
osilodrostat (n=36) or switch to placebo (n=35) for 8 weeks. Ineligible participants 
continued open-label osilodrostat. Period 4: all participants then received open-label 
osilodrostat until core-study end (W48). Primary objective: compare osilodrostat 
efficacy versus placebo at end of period 3. Primary endpoint: proportion of 
randomised participants with mUFC≤ULN at end of randomised withdrawal (W34), 
without up-titration during this period.  
 
Findings: 137 patients were enrolled. The primary objective was met: more patients 
maintained mUFC≤ULN with osilodrostat versus placebo at W34 (86·1% vs 29·4%; 
OR 13·7 [95%CI 3·7,53·4], P<0·001). At W24, 72/137 (52·6%; 95%CI 43·9,61·1) 
patients maintained mUFC≤ULN without up-titration after W12. At W48, 66·4% of 
enrolled patients had mUFC≤ULN. Most common adverse events (>25% of all 
patients): nausea (n=57, 41·6%), headache (n=46, 33·6%), fatigue (n=39, 28·5%), 
and adrenal insufficiency (n=38, 27·7%). Hypocortisolism and adverse events 
related to adrenal hormone precursors occurred in 70 (51·1%) and 58 (42·3%) 
patients, respectively.  
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Interpretation: Osilodrostat is an effective new treatment option for Cushing’s 
disease patients. 
 
Funding: Novartis Pharma AG. 
 




Cushing’s disease is a rare, serious disorder caused by an adrenocorticotropic 
hormone (ACTH)-secreting pituitary tumour, which stimulates the adrenal glands to 
overproduce cortisol.1 Excess cortisol leads to an increased mortality risk largely 
driven by cardiovascular disease and infections.2,3 First-line treatment for most 
patients is transsphenoidal surgery.4 However, additional second-line treatments are 
often needed as persistent or recurrent Cushing’s disease after surgery has been 
documented in approximately one-third of patients.2 For these patients or in cases 
where surgery or radiotherapy are not possible, medical therapies are used. Several 
options with various mechanisms of action are available, including a multireceptor-
targeted somatostatin analogue, dopamine receptor agonists, steroidogenesis 
inhibitors, adrenolytic agents, and glucocorticoid receptor antagonists.5 Despite the 
availability of multiple medical therapies, Cushing’s disease remains a difficult-to-
treat disorder that often necessitates a multimodal treatment approach.7-9 Additional 
effective and well-tolerated medical therapy options with alternative mechanisms of 
action are, therefore, needed to improve long-term outcomes for patients.10,11 
 
Osilodrostat (LCI699) is a potent, oral, reversible inhibitor of 11β-hydroxylase 
(CYP11B1), the enzyme that catalyses the final step of cortisol synthesis in the 
adrenal cortex. In a 22-week, prospective, Phase II study of osilodrostat in patients 
with Cushing’s disease (LINC 2),12,13 osilodrostat rapidly reduced mean urinary free 
cortisol (mUFC), leading to normalised mUFC in most patients (79%; n=15/19) at 
week 22. Treatment was generally well tolerated; the most common adverse events 
(AEs) included nausea, diarrhoea, asthenia, and adrenal insufficiency, mostly mild or 
moderate in severity.12 
 
The current manuscript reports the outcomes of a multicentre, open-label, Phase III 
study that assessed the efficacy and safety of osilodrostat in patients with Cushing’s 
disease (LINC 3; clinicaltrials.gov identifier: NCT02180217) and included a double-
blind randomised withdrawal phase. The study consisted of four phases to allow 
identification of effective osilodrostat dose within a narrow therapeutic window, to 
demonstrate the sustained safety and efficacy of osilodrostat (without the need for 
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further dose escalation), and to assess osilodrostat against placebo while minimising 
the duration of placebo treatment. To our knowledge, this is the first Phase III study 




Study design and procedures 
This was a prospective, multicentre (66 centres across 19 countries), open-label 
study with a double-blind randomised withdrawal phase following a 24-week, open-
label, single-arm treatment period (Figure 1). There were four study periods in the 
core phase. All participants initiated open-label oral osilodrostat 2 mg twice daily (bid 
[roughly every 12 hours]; 1, 5, 10, or 20 mg film-coated tablets for oral 
administration; Novartis Pharma AG, Basel, Switzerland), with dose adjustments 
every 2 weeks (range 1–30 mg bid) up to week 12 (study period 1) based on efficacy 
and tolerability. Dose was increased according to a 2 mg bid, 5 mg bid, 10 mg bid, 
20 mg bid, and 30 mg bid escalation sequence if mUFC (mean of three 24-hour 
samples) exceeded the upper limit of normal (ULN). Throughout the study, 
osilodrostat dose was reduced if mUFC was below the lower limit of normal (LLN), or 
if mUFC was in the lower part of the normal range in patients with symptoms of 
hypocortisolism or adrenal insufficiency. From weeks 13 to 24 (study period 2), 
osilodrostat was continued at the therapeutic dose determined during study period 1. 
In participants whose mUFC became elevated (>ULN), osilodrostat dose was 
increased (managed by a phone call to the patient between visits or by an 
unscheduled visit as soon as possible after receipt of mUFC results), if tolerated, but 
these participants were not randomised to the next study period. Participants were 
eligible to enter the randomised withdrawal phase at week 26 if they had mUFC 
≤ULN at week 24 without a dose increase after week 12; patients were randomised 
(1:1) in a double-blind manner to continue osilodrostat at the same therapeutic dose 
or receive matching placebo for 8 weeks without further dose increases (study 
period 3; as requested by regulatory authorities). Dose reductions/interruptions were 
permitted for safety reasons and did not preclude the possibility of a complete 
response at week 34. Participants not eligible for randomisation continued open-
label osilodrostat. After week 34, all participants received open-label osilodrostat 
until week 48 (study period 4). Osilodrostat dose could be adjusted throughout, 
depending on efficacy and tolerability. The dose schedule for osilodrostat was 
based, in part, on modelling data that estimated that a dose of 4–5 mg bid would 
achieve a plasma concentration above the in vitro 50% inhibitory concentration (IC50) 
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for 11β-hydroxylase (2·5 nM) for a full 24-hour period (Novartis Pharma AG, 
unpublished data). Furthermore, results of a Phase II study demonstrated that the 
dose of osilodrostat required to normalise mUFC ranged from 2 mg bid to 50 mg bid 
after individual dose titration.13 The lower starting dose of 2 mg bid and progressive 
up-titration to a maximal dose of 30 mg bid (based on individual clinical response 
and tolerability) were chosen to reduce potential risks of hypocortisolism and/or 
adrenal insufficiency. 
 
Participants could enter an optional, open-label extension phase for up to week 72 
as a minimum (ongoing in 2019). The study was conducted in accordance with the 
Declaration of Helsinki, with an independent ethics committee/institutional review 
board at each site approving the study protocol. 
 
Participants 
Adult patients (18–75 years of age) with confirmed persistent/recurrent Cushing’s 
disease after pituitary surgery and/or irradiation, or de novo patients who refused 
surgery or were not deemed to be surgical candidates, were eligible for inclusion. 
Confirmed active Cushing’s disease was evidenced at screening by a mean of two 
or three 24-hour UFC levels of ≥1·5 x ULN and morning plasma ACTH above the 
LLN. Inclusion criteria also required evidence of a pituitary origin for the excess 
ACTH based on one or more criteria: a pituitary tumour >6 mm by magnetic 
resonance imaging (MRI); a central-to-peripheral bilateral inferior petrosal sinus 
sampling gradient >2 pre- or >3 post-stimulation with either corticotrophin-releasing 
hormone or desmopressin acetate stimulation; and/or histopathological and 
immunohistochemical confirmation of an ACTH-producing pituitary tumour in 
patients with prior pituitary surgery. Patients receiving other medical therapies for 
Cushing’s disease could be included following a washout period of: 1 week for 
ketoconazole (n=36) and metyrapone (n=1); 4 weeks for cabergoline (n=18), 
rosiglitazone, pioglitazone, and mifepristone (n=4); 1 week for short-acting 
pasireotide/8 weeks for long-acting pasireotide (n=24); and 6 months for mitotane 
(n=1), followed by rescreening if required. Exclusion criteria included: stereotactic 
radiosurgery in the past 2 years; conventional radiotherapy in the past 3 years; 
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pituitary surgery in the past 29 days; treatment with other investigational drugs within 
30 days or five half-lives (whichever was longer); a history of hypersensitivity to 
osilodrostat or therapies of a similar chemical class; and presence or high risk of 
compression of optic chiasm. Although not a specific exclusion criterion, no 
participant had previously received osilodrostat. All patients provided written 
informed consent prior to participation. 
 
Randomisation and blinding 
For the double-blind randomised withdrawal phase starting at week 26, 
randomisation was performed via interactive-response technology (IRT). The 
investigator employed the IRT after confirming that the patient had fulfilled all 
randomisation criteria. A randomisation number was then assigned by the IRT to link 
the patient to a treatment group and unique medication number. Randomisation was 
stratified by osilodrostat dose at week 24 (≤5 or >5 mg bid) and history of pituitary 
irradiation (yes or no). Treatment identity was concealed by using identical 
packaging, labelling, schedule of administration, and tablet appearance and odour. 
To ensure that randomisation was concealed, a randomisation list was produced by 
the IRT provider using a validated system that automated the random assignment of 
patient numbers to randomisation numbers. Participants, investigators, and study 
sponsor as required were blinded from the time of randomisation until completion of 
the core study (week 48).  
 
Study endpoints and assessments 
The primary endpoint was the proportion of randomised participants who maintained 
a complete response to osilodrostat therapy or matching placebo (mUFC ≤ULN) 
without any dose increase during the randomised withdrawal period, at the end of 
the 8-week randomised withdrawal period (week 34). Patients discontinued the 
randomised withdrawal period and were considered non-responders for the primary 
endpoint if their mUFC increased to >1·5 x ULN and they had at least two urine 
samples with UFC >1·5 x ULN at a single visit. These patients resumed open-label 
osilodrostat. The key secondary endpoint was the proportion of participants with 
mUFC ≤ULN at the end of the single-arm, open-label period (week 24) without up-
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titration during weeks 13–24. Other secondary endpoints included: rates of complete 
response (mUFC ≤ULN) and partial response (mUFC >ULN but ≥50% reduction 
from baseline) at weeks 12, 24, and 48; change from baseline in mUFC, 
cardiovascular-related parameters (fasting plasma glucose, glycated haemoglobin 
[HbA1c], fasting lipid profile, sitting systolic and diastolic blood pressure, body weight, 
body mass index [BMI], and waist circumference), and patient-reported outcomes 
(health-related quality of life [HRQoL] assessed using the Cushing’s quality-of-life 
questionnaire [CushingQoL] and the Beck Depression Inventory [BDI]); maximum 
plasma concentration of osilodrostat (Cmax); and safety. A minimal important 
difference (MID; the smallest change in treatment outcome that an individual patient 
would identify as important) in CushingQoL score of 10·1 was defined based on the 
distribution method of a 0·5 standard deviation (SD) unit change using baseline data, 
with a 1-week recall period. An MID for improvement in BDI score was a 17·5% 
reduction in scores from baseline, as described previously.14 UFC was measured at 
a central laboratory (Q2 Solutions, Global Laboratory Services, Morrisville, NC, USA) 
using liquid chromatography–tandem mass spectrometry (LC-MS/MS; normal range 
11–138 nmol/24h [4–50 µg/24h]). Safety and tolerability were assessed by the 
investigators throughout the study, as required, by monitoring AEs according to 
Common Terminology Criteria for Adverse Events v4·03, which were coded using 
Medical Dictionary for Regulatory Activities (MedDRA) terminology. AEs of special 
interest (anticipated AEs) were those related to increase in adrenal hormone 
precursors, hypocortisolism, pituitary tumour enlargement, QT prolongation, and 
arryhthmogenic potential on electrocardiogram (ECG; assessed regularly throughout 
the study). Clinical and laboratory evaluations included total testosterone (LC-
MS/MS), plasma ACTH (Immulite 2000 ACTH kit), early-morning serum cortisol (LC-
MS/MS), serum 11-deoxycortisol (LC-MS/MS), late-night salivary cortisol (LC-
MS/MS), plasma aldosterone (LC-MS/MS), dehydroepiandrosterone sulfate 
(Chemiluminescent Immunoassay), 11-deoxycorticosterone (LC-MS/MS), active 
renin (Chemiluminescent Immunoassay), serum oestradiol (LC-MS/MS), and 
oestrone (LC-MS/MS). For normal ranges, see Supplementary Table 1. Tumour 
volume was assessed by MRI with gadolinium enhancement at baseline, week 24, 
and week 48 and was assessed centrally (Supplementary Methods). Mean 
percentage changes in tumour volume from baseline to week 48 were assessed for 
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all patients with evaluable measurements and by maximum tumour diameter at 
baseline (<6, 6‒<10, or ≥10 mm). For efficacy and safety evaluations, the last 
available pre-dose assessment within 35 days prior to or on the first day of 
osilodrostat treatment (before the first dose) was taken as the baseline assessment. 
 
Pharmacokinetic parameters for osilodrostat were determined by Phoenix WinNonlin 
v6·2 using non-compartmental analysis. Plasma samples from all participants were 
assayed for osilodrostat concentration using LC-MS/MS (lower limit of quantification 
for osilodrostat was 0·10 ng/mL). 
 
Statistical analyses 
Sample-size calculation was based on the primary endpoint. To detect a clinically 
meaningful difference of 40% in complete response rate (mUFC ≤ULN) between 
70% of patients in the osilodrostat arm and 30% in the placebo arm, a sample size of 
33 participants per arm was required based on a two-sided Cochran–Mantel–
Haenszel (CMH) test at the two-sided 0·05 level of statistical significance with 87% 
power. Assuming that ≥50% of participants enrolled would be eligible for 
randomisation, 132 participants needed to be enrolled. The primary analysis was 
based on the comparison of the proportion of participants with mUFC ≤ULN without 
a dose increase at the end of the 8-week randomised withdrawal period (ie at week 
34) between participants randomised to continue osilodrostat versus placebo. The 
statistical null hypothesis was that there would be no difference in the complete 
response rates between the two randomised arms. For the primary endpoint, testing 
was performed using the randomised analysis set composed of all randomised 
participants who received at least one dose of randomised treatment (osilodrostat or 
placebo) during period 3, following the intent-to-treat principle. If the CMH exact test 
two-sided P value was <0·05 and the odds ratio was >1, the null hypothesis would 
be rejected and the complete response rate in the osilodrostat arm considered 
higher than that in the placebo arm. For the key secondary objective, the statistical 
null hypothesis was that the complete response rate at the end of the 24-week open-
label period of osilodrostat treatment was ≤30%. Analysis of the key secondary 
objective was based on the two-sided 95% exact confidence interval (95% CI; 
 14 
Clopper–Pearson method). If the lower bound of this 95% CI was ≥30%, the 
secondary null hypothesis would be rejected, and a complete response rate of ≥30% 
after 24 weeks of treatment with osilodrostat would be concluded. Testing on the key 
secondary objective was only carried out if the null hypothesis for the primary 
objective was rejected to ensure preservation of the overall two-sided type 1 error at 
5%. Analysis of the key secondary endpoint was performed using the full analysis 
set composed of all enrolled participants who received at least one dose of 
osilodrostat. All statistical analyses were performed using SAS v9·4. Changes from 
baseline in secondary objective parameters are summarised descriptively. Safety 
was assessed using all data from first patient, first visit until the time the last patient 
completed or discontinued the core study (ie safety is reported beyond 48 weeks for 
some participants). The number and percentage of patients with AEs was tabulated 
by preferred term and CTCAE grade. For patients who discontinued the randomised 
withdrawal period and resumed open-label osilodrostat, AEs that occurred after 
withdrawal of randomised treatment were reported as part of the open-label 
osilodrostat phase. 
 
Role of funding source 
The funder of the study (Novartis Pharma AG) contributed to study design, data 
collection, data analysis, data interpretation, writing of the report, and decision to 
submit the report for publication. The funder also paid for the services of professional 
medical writers, who provided editorial assistance in developing the outline and 
subsequent drafts of the manuscript. All authors had full access to all the study data 
and were responsible for interpreting the data, writing the manuscript, and the 
decision to submit for publication. 
 15 
Results 
Patient population  
A total of 202 patients were screened and 137 were enrolled between 12 November 
2014 and 22 March 2017 to receive open-label osilodrostat (Figure 2). At week 26, 
71 patients (51·8%) were randomised to continue osilodrostat (n=36) or matching 
placebo (n=35; Figure 2). Nineteen patients discontinued treatment prior to the 
randomised withdrawal phase (AEs, n=12; patient withdrew consent, n=4; physician 
decision, n=2; patient/guardian decision, n=1), and one patient met randomisation 
criteria but was not randomised in accordance with the investigator’s decision. Of the 
remaining 46 patients not randomised, 20 did not meet the mUFC normalisation 
criteria at week 24, and 26 had dose increases beyond that established at week 12 
(end of the dose-titration period), although 19 of these 26 patients later met the 
mUFC normalisation criteria at week 24. Among the enrolled patients, 106 (77·4%) 
entered the ongoing extension phase.  
 
Baseline patient characteristics were generally balanced between randomised 
groups, although median mUFC was higher in patients randomised to osilodrostat 
versus placebo (457 vs 358 nmol/24h; Table 1). Median mUFC was similar between 
patients randomised to osilodrostat and placebo at the start of the randomised 
withdrawal period (week 26; 57·6 vs 57·0 nmol/24h, respectively).  
 
Exposure to osilodrostat 
By week 24, the majority of patients (62·0%) were receiving an osilodrostat dose of 
≤5 mg bid, irrespective of severity of mUFC elevation at baseline, with only 5·8% of 
patients requiring a dose of >10 mg bid. During the first 26 weeks, mean (SD) dose 
received was 10·0 (7·3) mg/day, and mean (SD) highest dose was 17·8 (13·6) 
mg/day; 100 patients (73·0%) had a dose reduction during the first 26 weeks. During 
the randomised withdrawal phase, mean (SD) dose was 10·0 (9·6) mg/day. In total, 
121 patients (88·3%) were treated for >24 weeks, with 105 patients (76·6%) 
exposed to osilodrostat for at least 48 weeks (core phase). Median (IQR) exposure 
was 74·7 (48·1–117·0) weeks (including the 48-week core phase plus extension 
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data up to the data cut-off date, when all patients had completed the core period of 
the study or discontinued early). In total, 42/137 (30·7%) patients received at least 
one dose of osilodrostat different to that planned in the protocol. 
 
Pharmacokinetic exposure of osilodrostat 
Mean Cmax increased with increasing doses of osilodrostat during the initial 12-week 
dose-titration period. At the end of the dose-titration period (week 12), mean plasma 
osilodrostat concentration was 4·5 ng/mL and 54·0 ng/mL, respectively, 2 hours after 
a 1 mg (n=16) and 10 mg (n=20) incident dose. 
 
Efficacy of osilodrostat 
Primary efficacy endpoint 
The primary efficacy endpoint was met and the null hypothesis rejected. At the end 
of the randomised withdrawal phase (week 34; study period 3), mUFC ≤ULN was 
maintained without any dose increase in statistically significantly more patients who 
continued osilodrostat treatment versus placebo (86·1% [n=31/36] vs 29·4% 
[n=10/34]; odds ratio: 13·7 [95% CI 3·7, 53·4], P<0·001; Figure 3a and Table 2); 
intrapatient changes in mUFC levels are shown in Supplementary Figure 1. One 
patient randomised to the placebo arm did not receive treatment because of an AE 
(glucocorticoid deficiency), which required drug interruption. A consistent treatment 
effect was observed irrespective of randomisation stratum (week 24 dose ≤5 or 
>5 mg bid and history of pituitary irradiation; Table 2). 
 
Of the 10 patients randomised to placebo who maintained mUFC ≤ULN at the end of 
the randomised withdrawal period, seven had study baseline mUFC <2 x ULN, two 
had mUFC 2–5 x ULN, and one had mUFC ≥5 x ULN. All 10 patients had undergone 
prior neurosurgery (most recently ≥6 months prior to enrolment), and one patient had 
received prior pituitary irradiation. Of the three patients with baseline mUFC >2 x 
ULN, all were receiving osilodrostat ≤2 mg bid at week 24.   
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Key secondary endpoint 
The key secondary endpoint was also met. At week 24 (end of study period 2), 
52·6% (n=72/137; 95% CI 43·9, 61·1) of all patients maintained mUFC ≤ULN without 
a dose increase after week 12 (end of study period 1). The lower bound of the  
95% CI exceeded the prespecified threshold for a statistically significant clinical 
benefit (30%). Irrespective of dose increase, in total, 93/137 patients (67.9%) 
normalised mUFC by week 24. Individual changes in mUFC from baseline to week 
24 for all enrolled patients are shown in Figure 3b. 
 
Other secondary endpoints 
Overall, mean mUFC decreased rapidly during the initial 12-week osilodrostat dose-
titration period (study period 1), then remained below baseline values throughout the 
study (Supplementary Figure 2a). Mean serum and salivary cortisol also decreased 
rapidly in the first 12 weeks, then remained below baseline values and the ULN 
(Supplementary Figure 2b–d); however, slight increases were seen in patients 
randomised to placebo between weeks 28 and 34.  
 
Most enrolled patients (96·4%) achieved mUFC ≤ULN at least once during the study, 
with no differences observed in males versus females; median time to first complete 
response was 41 days. In addition, 64/97 (66·0%) patients maintained normal mUFC 
(mUFC ≤ULN) for at least 6 months after the first mUFC normalisation. At the end of 
the core phase (week 48), 66·4% of all enrolled patients had controlled mUFC 
(Supplementary Table 2).  
 
Changes in clinical and laboratory parameters 
Overall, improvements were observed from baseline in most evaluated 
cardiovascular-related metabolic parameters associated with hypercortisolism, 
including weight, BMI, glucose, systolic/diastolic blood pressure, and total 
cholesterol (Supplementary Table 3). Mean (SD) CushingQoL score improved by 
52·4% (107·4), and BDI score improved by 31·8% (65·0), by week 48. Changes in 
CushingQoL score reached the distribution-based MID of a 10·1-point change from 
baseline at weeks 26, 30, 32, 34, and 48. Changes in BDI score reached the MID of 
 18 
a 17·5% reduction from baseline at weeks 24, 26, 28, 30, and 48. Most 
improvements in clinical and laboratory parameters were evident during the dose-
titration period (up to week 12, study period 1) and were generally maintained 
throughout the study (Supplementary Table 4), including the 8-week randomised 
withdrawal period, although this was a short time frame.  
 
Safety and tolerability 
All patients experienced at least one investigator-reported AE during the study, most 
frequently nausea (41·6%), headache (33·6%), fatigue (28·5%), and adrenal 
insufficiency (27·7%; Supplementary Table 5). The most frequently reported grade 
3/4 AEs were adrenal insufficiency (4·4%), glucocorticoid deficiency (3·6%), 
headache (2·9%), and vomiting (2·9%). 
 
A similar proportion of patients randomised to continue osilodrostat treatment or 
switch to placebo had AEs during the randomised withdrawal period (72·2% and 
65·7% in the osilodrostat and placebo groups, respectively). The most commonly 
reported AEs in the osilodrostat group during the randomised withdrawal were 
nausea (11·1% [n=4] vs 0% for placebo), anaemia (8·3% [n=3] vs 8·6% [n=3]), 
arthralgia (8·3% [n=3] vs 0%), and headache (8·3% [n=3] vs 0%; Table 3). Arthralgia 
was often considered by the treating investigator to be related to the underlying 
disease or other pathologies (including injuries).  
 
Hypocortisolism-related AEs were clinically assessed and reported by the 
investigators in 51·1% of all patients at any point during the study (Supplementary 
Table 5), most commonly being classified as adrenal insufficiency (27·7%) or 
glucocorticoid deficiency (21·2%), which reflect the same condition. They mostly 
occurred and resolved during the dose-titration period (study period 1), were typically 
single episodes of grade 1–2, and were managed by dose reductions/interruptions 
and corticosteroid supplementation when clinically indicated. In total, 25 patients with 
≥1 hypocortisolism-related AE required treatment with glucocorticoids. In general, 
UFC values closest to the occurrence of these events did not fall below the LLN (ie 
the AE occurred concurrently with a rapid decrease in pathologically high cortisol 
 19 
levels, which were still >ULN or within the normal range). No relationship was 
observed between the dose of osilodrostat or baseline UFC and the occurrence of 
hypocortisolism-related AEs.  
 
AEs potentially related to increases in adrenal steroid precursors occurred in 42·3% 
of patients during the study (mostly grade 1–2; Supplementary Table 5), most 
commonly reported as hypokalaemia (13·1%) and hypertension (12·4%). Although 
serum potassium was generally maintained within the normal range, there was a 
trend for greater decreases in mean serum potassium levels with increasing 
osilodrostat Cmax (Supplementary Figure 3). The lowest reported serum potassium 
value observed in the seven patients who experienced newly occurring grade 3/4 
hypokalaemia was 2·4 mmol/L (normal range 3·5–5·3 nmol/L). Episodes were 
treated with potassium supplements, spironolactone, and/or dose 
reduction/interruption.  
 
No male patients experienced signs or symptoms related to increases in androgens 
or oestrogens during the study. In female patients, AEs of hirsutism (8·8%; 
n=12/137), acne (8·8%; n=12/137), and hypertrichosis (0·7%; n=1/137) were 
reported; all were grade 1–2 and none led to study discontinuation. An AE of QT 
prolongation (defined as notable ECG abnormalities [eg QTcF >480 ms or >60 ms 
increase from baseline]) was reported in five (3·6%) patients (QTcF values <480 ms 
at all time points); all were reported as non-serious, which resulted in dose 
adjustment or interruption in three patients and discontinuation in one patient. 
 
In total, 18 (13·1%) patients discontinued treatment because of an AE by the time of 
the data cut-off, most commonly adrenal insufficiency (n=4, 2·9%) and pituitary 
tumour (n=4, 2·9%), reported as ‘pituitary tumour enlargement’, ‘pituitary tumour 
volume increase’, ‘increased adenoma size’, or ‘pituitary tumour growth’. Of the four 
patients with pituitary tumour, two had macroadenomas and two had 
microadenomas at baseline.  
 
Overall, 81 (59·1%) patients had a measurable pituitary tumour at baseline (n=13/81 
[16·0%] macroadenoma [≥10 mm], n=68/81 [84·0%] microadenoma [<10 mm]). 
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Seventy-nine patients (57·7%) had a measurable tumour at both baseline and at 
least one post-baseline assessment. A similar proportion of patients had either a 
≥20% decrease or ≥20% increase from baseline in tumour volume at week 24 
(30·3% and 28·8%, respectively) and week 48 (37·5% and 32·8%, respectively). 
Similar results were observed irrespective of maximum tumour diameter at baseline 
(<10 or ≥10 mm). At data cut-off, four patients with a ≥20% increase from baseline in 
tumour volume and 13 with a ≥20% decrease had received prior pituitary irradiation.   
In those patients with no tumour identifiable at baseline, none had evidence of a 
newly measurable pituitary tumour identified by MRI during the study. 
 
One death occurred, which was not considered to be related to the study drug – the 
patient died by suicide during the extension phase (day 551) in the context of an 
extensive psychiatric history. The patient, who was randomised to placebo, had 
mUFC within the normal range during osilodrostat treatment. 
 
All enrolled patients received concomitant medications and significant non-drug 
therapies during the study. Concomitant medications were mainly prescribed to 
manage AEs. During the study, 97 (70·8%) patients received one or more 
antihypotensive or antihypertensive medications (72/137 [52·6%] patients were 
newly started during the study), 50 (36·5%) received antidiabetic medications 
(23/137 [16·8%] patients newly started), and 34 (24·8%) received lipid-lowering 
treatments (13/137 [9·5%] patients newly started; most commonly statins).  
 
Effect of osilodrostat on other hormones 
In the overall population, mean (SD) ACTH levels were >ULN (18·4 [35·5] pmol/L) at 
baseline and increased during the study to 50·0 (69·7) pmol/L at week 48. No 
association was observed between ACTH and cortisol levels (Pearson’s correlation 
coefficient at week 48: –0.10) [Supplementary Table 6]. The increase was reversed 
during the randomised withdrawal phase in patients randomised to placebo 
(Supplementary Figure 4). Mean (SD) 11-deoxycortisol also increased over time 
from 3·4 (2·6) nmol/L at baseline in male patients and 6·3 (20·1) nmol/L in female 
patients to 23·3 (24·8) and 36·6 (36·9) nmol/L, respectively, at week 48. Increases in 
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mean 11-deoxycortisol were also reversed during the randomised withdrawal phase 
in patients randomised to placebo (Supplementary Figure 5a and 5b). An increase in 
mean testosterone was seen in both male and female patients during the first 12 
weeks, which stabilised thereafter (Supplementary Figure 6a and 6b). Mean (SD) 
testosterone levels in males increased from 9·5 (5·8) nmol/L at baseline to 17·7 (8·0) 
nmol/L at week 48; for individual patients, testosterone levels tended to increase 
from the low to the middle of the normal range, with no values above the ULN 
reported for last available values. For some hypogonadal patients, testosterone 
increased from <LLN into the normal range during osilodrostat treatment. In females, 
mean (SD) testosterone increased from 1·3 (1·2) nmol/L at baseline to 2·6 (2·4) 
nmol/L at week 48. In male and female patients, a mild increase in gonadotrophin 
levels was seen from baseline, although we cannot exclude effects of spontaneous 
recovery of post-surgical damage of the gonadotropic pituitary cells. Compared with 
baseline, gradual reductions were seen in plasma aldosterone and 
dehydroepiandrosterone sulphate, and gradual increases were seen in 11-
deoxycorticosterone, renin, serum oestradiol, and oestrone (Supplementary 
Figure 7a–f). No clear trend was observed between absolute 11-deoxycorticosterone 
levels and systolic blood pressure or serum potassium levels, or between changes 
from baseline in these parameters (data not shown). 
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Discussion 
This large, prospective study is, to our knowledge, the first Phase III trial of a medical 
therapy for patients with Cushing’s disease to include a randomised, double-blind, 
placebo-controlled period. The study met both its primary and key secondary 
endpoints. At the end of the 8-week, blinded, randomised withdrawal, placebo-
controlled phase (study period 3), a statistically significant higher proportion of 
patients in the osilodrostat arm maintained normal mUFC versus placebo. These 
findings were seen irrespective of randomisation stratum, confirming that prior 
irradiation and higher osilodrostat dose were not driving factors for mUFC response.  
 
For the patients receiving placebo who maintained a complete response, the last 
mUFC value during the withdrawal phase was higher than that at randomised 
withdrawal baseline in 9/10 patients but still within the normal range, with all patients 
showing a progressive increase in mUFC during this period; a longer withdrawal 
period would likely have resulted in a higher proportion of patients receiving placebo 
experiencing elevated mUFC. These results are consistent with findings from a 10-
week proof-of-concept study of osilodrostat in patients with Cushing’s disease 
(N=12), in which mUFC levels remained below ULN in some patients following a 2-
week washout of osilodrostat.13 It is possible that mild cases of Cushing’s disease, 
as evident in the majority of these patients with mUFC <2 x ULN at study baseline, 
and/or fluctuations in mUFC may have influenced our findings. However, the 
statistically significant difference in complete response between the two arms 
strongly indicates a benefit with osilodrostat. A delay in cortisol recovery following 
osilodrostat withdrawal in some patients is also a possibility. No association was 
observed between ACTH and cortisol levels in our study. In addition, a delay in 
cortisol increase above the ULN in some patients is not fully explained by the 
reversible inhibitory effect of osilodrostat on 11β-hydroxylase, while there is no 
evidence supporting a cytolytic effect of osilodrostat on adrenal tissue or prolonged 
action on the hypothalamic–pituitary–adrenal axis. As such, the reason underlying a 
delayed increase in cortisol above the ULN in some patients after osilodrostat 
withdrawal is unknown and further investigation would be of interest. 
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Patients experienced a rapid reduction in mUFC during the initial 24-week open-
label phase, which included the dose-titration (study period 1) and therapeutic-dose 
periods (study period 2). More than half (52.6%) of the patients enrolled achieved 
the key secondary endpoint of mUFC ≤ULN at week 24 without dose up-titration 
after week 12. Furthermore, most patients (96·4%) achieved mUFC ≤ULN at some 
point during osilodrostat treatment, with 66·0% of patients maintaining mUFC ≤ULN 
for at least 6 months after first mUFC normalisation, indicating that osilodrostat 
provides sustained control of mUFC levels in a majority of patients. Although most 
patients achieved mUFC ≤ULN at some point during the study, a lower proportion of 
all patients (66·4%) had mUFC ≤ULN at the end of the core phase. This may be 
explained by day-to-day fluctuations in mUFC measurements, but also because 
patients who discontinued before week 48 were counted as non-responders, 
affecting the overall proportion of patients with mUFC ≤ULN by the end of the core 
study. Reductions in mean morning serum and late-night salivary cortisol 
accompanied the reductions in mean mUFC, further strengthening our conclusion of 
a benefit with osilodrostat treatment for patients with Cushing’s disease. In a recent 
Phase III study of the investigational agent levoketoconazole, a steroidogenesis 
inhibitor, 29/94 (31%) patients with Cushing’s syndrome achieved mUFC ≤ULN 
following an initial dose-titration period and 6 months of maintenance therapy 
(without a dose increase during the maintenance phase).11 
 
Reductions in mUFC during 48 weeks of osilodrostat treatment were accompanied 
by improvements in weight, BMI, glucose, systolic/diastolic blood pressure, and total 
cholesterol. Improvements occurred soon after osilodrostat initiation and were 
sustained until the end of the study. Given the known clinical burden of 
cardiovascular risk associated with Cushing’s disease,2 demonstrated by the 
abnormal baseline values of many participants in this study, the improvement in 
clinical features shown here represent important benefits of osilodrostat. By 
improving multiple cardiovascular risk factors, our findings are likely to be clinically 
relevant. The slight decrease in HDL cholesterol observed at week 48 was similar to 
that described in a study of mifepristone (a glucocorticoid receptor antagonist) for the 
treatment of Cushing’s syndrome;15 further investigation concluded that such a 
reduction would not adversely affect cardiovascular risk.16 Osilodrostat also led to 
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clinically meaningful improvements in HRQoL throughout the study from week 12, 
including CushingQoL score, despite considerable impairments at baseline 
associated with prolonged hypercortisolism.17 Clinically meaningful improvements in 
depression as assessed by BDI score were also evident throughout the study, 
representing clinical benefit following osilodrostat treatment. Future evaluation of 
other manifestations of cortisol excess, including menstrual abnormalities, which 
often resolve following normalisation of cortisol levels,18 as well as facial rubor, 
striae, muscle wasting, and bone loss, would be of considerable interest given the 
potential deleterious effects they can exert on quality of life and morbidity.3 
 
Osilodrostat was generally well tolerated; commonly reported AEs were as expected 
based on its mechanism of action. They were consistent with those reported during 
the 22-week Phase II study.12 The majority of patients (82·5%) completed the 48-
week study, with a low rate of discontinuations due to AEs (13·1%) and one death, 
which was not attributed to osilodrostat. The most commonly reported AEs of special 
interest (associated with osilodrostat) were related to hypocortisolism, highlighting 
the potency of osilodrostat; these were generally managed by dose adjustments 
and/or corticosteroid supplementation. These AEs were mostly mild to moderate in 
severity and mainly occurred during the initial dose-titration period, as was also 
found when using either metyrapone19 or ketoconazole.20 As most AEs occurred 
during the rapid dose up-titration period (forced dose increases every 2 weeks if 
mUFC >ULN), we anticipate that smaller dose increases and/or more gradual dose 
up-titration (except in cases of severely ill patients who require rapid cortisol control) 
might reduce the rate of AEs related to hypocortisolism in clinical practice. Indeed, in 
the interests of safety, the rate of mUFC decrease was considered by many 
investigators when making dose-titration decisions during the study and, as a result, 
some patients with mUFC >ULN did not receive a dose increase as specified in the 
protocol. 
 
Elevations in liver transaminases were infrequent, typically mild, and reversed 
spontaneously or following dose adjustment. AEs of hypertension and low serum 
potassium, potential outcomes of inhibiting 11β-hydroxylase, which causes the 
accumulation of precursor mineralocorticoids such as 11-deoxycorticosterone, were 
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reported in only a few patients; there was no clear indication of a causal relationship 
(data not shown). However, it is possible that changes in concomitant blood 
pressure control medications could have contributed to the lack of correlation 
between 11-deoxycorticosterone levels and blood pressure. These data suggest that 
the inhibition of 11β-hydroxylase with osilodrostat is, therefore, not a phenocopy of 
classic congenital 11β-hydroxylase deficiency.21-25 In addition to inhibiting 11β-
hydroxylase, osilodrostat is known to inhibit aldosterone synthase in a dose-
dependent manner, as well as basal and ACTH-stimulated cortisol secretion at 
specific doses.26 Increases in precursors to cortisol and aldosterone, as well as 
ACTH, were observed. The expected physiological rise in ACTH that is associated 
with a reduction in cortisol levels likely contributed to the observed increases in 
adrenal steroid precursors; however, resultant AEs rarely led to drug discontinuation 
and were generally managed with conventional medications. Generally, no specific 
action was required for increases in ACTH, 11-deoxycortisol or 11-
deoxycorticosterone. Furthermore, increases were reversible upon discontinuation of 
osilodrostat, as seen in the placebo arm during the randomised withdrawal period. 
Owing to the increase in serum 11-deoxycortisol induced by osilodrostat therapy, it is 
important that assays measuring cortisol have no cross-reactivity with this precursor, 
and this is most readily achieved by using a mass spectrometry assay for cortisol, as 
was done here.27 Mean testosterone levels increased in male and female patients, 
but the increases were mild to moderate and did not lead to study discontinuation in 
any patient. Osilodrostat treatment did not adversely affect pituitary tumour size, with 
a small proportion of patients experiencing ≥20% decrease or ≥20% increase from 
baseline in tumour volume. Longer-term follow-up would be needed to further 
evaluate changes in tumour volume during osilodrostat treatment. 
 
Although the study permitted the inclusion of patients aged 18–75 years, enrolled 
participants were aged 19–70 years; as such, our study provides no data for patients 
aged >70 years and therefore further evaluation of osilodrostat in older patients may 
be of interest. Our data are also limited by the short, randomised withdrawal period. 
The 8-week withdrawal period was not long enough to confirm whether withdrawal of 
osilodrostat would have resulted in worsening clinical signs and features of 
hypercortisolism. Longer-term follow-up to assess both duration of effectiveness and 
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long-term safety of osilodrostat will be important. Assessment of serum and/or 
salivary cortisol levels across a 24-hour period would be valuable in order to further 
explore the pharmacodynamic effect of twice-daily osilodrostat, including on the 
restoration of cortisol diurnal rhythm, which is frequently disrupted in patients with 
Cushing’s disease.28 It should also be noted that nearly all patients received 
concomitant medications during the study, including antihypertensive and 
antidiabetic medications, and we are unable to exclude the possibility that they may 
have influenced some findings. Further examination of the effects of osilodrostat on 
the clinical signs of Cushing’s disease, as well as the reasons for changes in 
concomitant medications and the relationship between such medications and 
associated clinical outcomes, would be valuable. 
 
In conclusion, the results of this prospective, Phase III study, which included a 
double-blind randomised withdrawal phase, demonstrate that osilodrostat rapidly 
reduces mUFC as well as serum cortisol and sustains these reductions alongside 
improvements in clinical signs of hypercortisolism, CushingQoL score, and 
depression without unexpected side effects. Alongside careful dose adjustments and 
monitoring of known risks associated with osilodrostat, our findings indicate a 
positive benefit–risk consideration of treatment for most patients with Cushing’s 
disease.  
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Research in context 
Evidence before this study  
In June 2014, during the development of the study protocol, we reviewed the 
literature using PubMed (no date restrictions; search terms “Cushing’s disease”, 
“pituitary gland”, and “adrenocorticotropic hormone”), which highlighted that despite 
advances and recent approval of medical therapies to treat Cushing’s disease (eg 
pasireotide and mifepristone), a substantial proportion of patients with Cushing’s 
disease do not achieve and maintain normalisation of mean urinary free cortisol 
(mUFC), a key treatment goal in such patients. As such, there remained an unmet 
medical need to develop additional new and effective drugs, as patients often require 
multimodal treatment and more options may allow better tailoring of treatment. 
Based on earlier Phase I and Phase II studies in patients with Cushing’s disease, 
osilodrostat, a potent oral inhibitor of 11β-hydroxylase, showed promise in fulfilling 
this unmet need. 
 
Added value of this study  
This is the first Phase III study of any medical therapy to include a placebo-controlled 
period in patients with Cushing’s disease. LINC 3 was a prospective, multicentre, 
open-label study with a double-blind randomised withdrawal phase following a 24-
week, open-label, single-arm treatment period. Osilodrostat was superior to placebo 
(statistically significant) at maintaining mUFC ≤ULN after randomised withdrawal and 
normalised mUFC in two-thirds of enrolled patients by the end of the study (week 
48). Osilodrostat was shown to be generally well tolerated, with no unexpected side 
effects and few patients discontinuing treatment because of adverse events. 
 
Implications of all the available evidence  
This study demonstrates that osilodrostat rapidly reduces elevated mUFC and 
cortisol production and sustains this reduction alongside improvements in clinical 
signs of hypercortisolism, CushingQoL score, and depression without unexpected 
side effects. As such, osilodrostat is a promising new treatment option for patients 
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with Cushing’s disease. Further evaluation of osilodrostat in patients with other 
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Table 1. Summary of patient demographics and baseline characteristics, 
overall (full analysis set) and by randomised treatment group 
 Randomised treatment group 
(randomised withdrawal phase) 
 


















Male:female, n:n 6:30 13:22 12:54 31:106 

























Median time since 










surgery, n (%) 
32 (88·9) 33 (94·3) 55 (83·3) 120 (87·6) 
Previous medical 
therapy for Cushing’s 
disease, n (%) 
26 (72·2) 24 (68·6) 52 (78·8) 102 (74·5) 
Previous pituitary 
irradiation, n (%) 
6 (16·7) 5 (14·3) 11 (16·7) 22 (16·1) 
mUFC, nmol/24h 
























*One patient in the placebo group (25-year-old female with persistent/recurrent Cushing’s disease 
after previous pituitary surgery; mUFC level at screening: 2037·2 nmol/24h [14·8 x ULN]) was 
randomised but did not receive any allocated treatment during the randomised withdrawal period. 
ULN for mUFC is 138 nmol/24h. IQR, interquartile range 
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Table 2. Proportion of primary efficacy responders at week 34 by randomised 
treatment and stratum 
   Cochran–Mantel–
Haenszel exact test 
 Responders/N 
(%) 



















Osilodrostat dose at week 24 ≤5 mg 




















Osilodrostat dose at week 24 ≤5 mg 




















Osilodrostat dose at week 24 >5 mg 









   
Osilodrostat dose at week 24 >5 mg 
bid and without history of pituitary 
irradiation 
  Osilodrostat 

















NE, not evaluable 
 
 36 
Table 3. Summary of adverse events (all grades and grade 3/4) in either 
treatment group during the randomised withdrawal phase 
 Randomised treatment group  
(randomised withdrawal phase) 




 All grades, n 
(%) 






Any AE 26 (72·2) 2 (5·6) 23 (65·7) 3 (8·6) 
Any serious AE 2 (5·6) 1 (2·8) 1 (2·9) 1 (2·9) 
AEs requiring dose adjustment 7 (19·4) NA 5 (14·3) NA 
Anticipated AEs of special interest  
Adrenal hormone precursor 
accumulation related 
2 (5·6) 0 1 (2·9) 0 
Hypocortisolism related 3 (8·3) 0 1 (2·9) 0 
Pituitary tumour enlargement 
related 
0 0 0 0 
QT prolongation related 0 0 0 0 
Arrhythmogenic potential 0 0 0 0 
Most common study­emergent AEs (occurring in >5% of patients in either group) 
Nausea 4 (11·1) 0 0 0 
Anaemia 3 (8·3) 0 3 (8·6) 0 
Arthralgia 3 (8·3) 0 0 0 
Headache 3 (8·3) 0 0 0 
Asthenia 2 (5·6) 0 0 0 
Blood corticotrophin increased 2 (5·6) 0 1 (2·9) 1 (2·9) 
Constipation 2 (5·6) 0 0 0 
Depression 2 (5·6) 0 1 (2·9) 0 
Dizziness 2 (5·6) 0 1 (2·9) 0 
Fatigue 2 (5·6) 0 3 (8·6) 1 (2·9) 
Hirsutism 2 (5·6) 0 1 (2·9) 0 
Nasopharyngitis 2 (5·6) 0 1 (2·9) 0 
UFC decreased 2 (5·6) 0 1 (2·9) 0 
Cough 1 (2·8) 0 2 (5·7) 0 
Insomnia 1 (2·8) 0 2 (5·7) 0 
Urinary tract infection 1 (2·8) 0 2 (5·7) 0 
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Diarrhoea 0 0 2 (5·7) 0 
Gastro-oesophageal reflux disease 0 0 2 (5·7) 0 




Figure 1. Study design and dosing schedule 
*Based on efficacy and tolerability 
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Figure 2. Patient disposition flow chart 
 
*Including unacceptable test procedure results, laboratory values, past medical history, and use 
of excluded medications; †(Before week 12) rash (n=1), visual impairment (n=1), 
headache/paresis cranial nerve/pituitary tumour benign (n=1), AE not recorded (n=1); ‡(Weeks 
12–26) adrenal insufficiency (n=2), hypokalaemia/adrenal insufficiency (n=1), pain in 
extremity/fatigue (n=1), systolic/diastolic blood pressure increased (n=1), asthenia (n=1), pituitary 
tumour benign (n=1), malignant pituitary tumour (n=1); §(Randomised withdrawal, placebo – week 
48) hyponatraemia (n=1), increased ACTH/pituitary tumour (n=1; occurred during the open-label 
period following randomised withdrawal); ¶(Non-randomised) pituitary tumour (n=1) 
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Figure 3. Individual changes in mUFC a) during the randomised withdrawal 
phase, by randomised treatment group and b) from baseline to week 24 
 
mUFC ULN = 138 nmol/24h. For (b), patients are shown in order of decreasing baseline mUFC 
value. Five patients had mUFC ≤ULN at baseline; however, mUFC was ≥1·5 x ULN at screening, 





Principal investigators (including non-author contributors/collaborators; N=total 
number of patients enrolled in the study, n=number of patients included in the 
randomised withdrawal period): Argentina: Susana Mallea-Gil (Atencion Integral 
Reumatologia; N=1, n=1), Karina Miragaya (Sanatorio Guemes; N=1, n=0); Austria: 
Anton Luger (Univ Klinik fuer Innere Medizin III AKH Wien; N=3, n=1); Bulgaria: 
Sabina Zaharieva (Akad. Ivan Penchev; N=3, n=1); Canada: Ghislaine Houde 
(CHUS – Hopital Fleurimont; N=3, n=0), Andre Lacroix (CHUM Hotel Dieu; N=5, 
n=4), Syed Ali Imran (Capital District Health Authority, QEII Health Sciences Centre; 
N=2, n=0), Constance Chik (University of Alberta; N=1, n=0); China: Feng Gu 
(Peking Union Medical College Hospital; N=1, n=0), Yerong Yu (West China Hospital 
of Sichuan University; N=2, n=0), Xiaohui Guo (Peking University First Hospital; 
N=1, n=1); Colombia: Alin Abreu (Centro Medico Imbanaco de Cali; N=2, n=1); 
France: Jerome Bertherat (Hopital Cochin; N=1, n=1), Jacques Young (Hopital 
Kremlin Bicetre; N=1, n=0), Antoine Tabarin (CHU Bordeaux; N=3, n=1), Thierry 
Brue (AP-HM – Hôpital de la Conception; N=3, n=0), Olivier Chabre (CHU de 
Grenoble; X=0), Marie-Christine Vantyghem and Jean-Louis Wemeau (CHRU de 
Lille Hopital Claude Huriez; N=1, n=0); Germany: Jochen Schopohl (Facharztpraxis 
fur Innere Medizin; N=2, n=1), Christof Schoefl and Flavius Zoicas 
(Universitätsklinikum Erlangen-Nürnberg; N=3, n=1), Jörg Flitsch (Univ.-Klinikum 
Eppendorf; X=0), Michael Droste (Praxis f. Endokrinologie und Diabetologie; X=0); 
India: HS Asha and Nitin Kapoor (Christian Medical College & Hospital; N=1, n=0), 
Pramila Kalra (M S Ramaiah Memorial Hospital; N=1, n=0), Rama Walia (PGIMER; 
N=3, n=0), Jyotsna Viveka (All India Institute of Medical Sciences; N=2, n=0); Italy: 
Giovanna Mantovani and Annamaria Spada (Fond. IRCCS Ca’Granda Ospedale; 
N=1, n=0), Marco Boscaro (Azienda Ospedaliera di Padova Università degli Studi; 
N=4, n=2), Diego Ferone (Ospedale Policlinico San Martino IRCCS; N=1, n=0), 
Giorgio Arnaldi (AOU Osp. Riuniti Umberto I-GM Lancisi – G. Salesi-Univ. Studi; 
N=2, n=1), Rosario Pivonello (Università Federico II di Napoli; N=10, n=5), Salvatore 
Cannavò (Az. Ospe. Universitaria Policlinico G. Martino Univ. di Messina; N=1, n=0), 
Fausto Bogazzi (Az. Ospedaliero Universitaria Pisana; N=1, n=0); Japan: Shigeyuki 
 42 
Tahara (Nippon Medical School Hospital; N=1, n=0), Erina Shigematsu (NHO 
Yokohama Medical Center; N=1, n=0), Akira Kanazawa (Tokyo Medical University 
Hospital; N=1, n=0), Noriyuki Suzaki (National Hospital Organization Nagoya 
Medical Center; N=2, n=1), Hidenori Koyama (Hyogo College of Medicine Hospital; 
N=2, n=0), Shigeru Nishizawa and Junkoh Yamamoto (University of Occupational 
and Environmental Health; X=0), Kenji Ashida and Masatoshi Nomura (Kyushu 
University Hospital; N=1, n=0), Yutaka Takahashi (Kobe University Hospital; N=1, 
n=1); Korea: Jung Hee Kim (Seoul National University College of Medicine; N=5, 
n=2), Kyu Yeon Hur (Samsung Medical Center; N=1, n=0), Eun Jig Lee (Severance 
Hospital, YUHS; N=8, n=3); Netherlands: Richard Feelders (Erasmus University 
Medical Center; N=4, n=0); Russia: Zhanna Belaya (Center for Endocrinology 
Russian Academy of Med Sciences; N=4, n=0); Spain: Alfonso Soto-Moreno 
(Hospital Virgen del Rocio; N=2, n=1), Cristine Alvarez-Escola (Hospital La Paz; 
N=1, n=1), Rogelio Garcia-Centeno (Hospital General Universitario Gregorio; N=2, 
n=1); Thailand: Rattana Leelawattana (Prince of Songkla University; N=5, n=2); 
Turkey: Pinar Kadioglu (Istanbul University Cerrahpasa Faculty of Medicine; N=4, 
n=2); UK: Peter Trainer (The Christie NHS Foundation Trust; X=0), John Newell-
Price (University of Sheffield; N=1, n=1), Scott Akker (Barts and the London NHS 
Trust; X=0); USA: Maria Fleseriu (Oregon Health & Science University; N=4, n=2); 
Beverly Biller (Massachusetts General Hospital; N=1, n=0), James Findling (Medical 
College of Wisconsin; N=4, n=3), Eliza Geer (Mount Sinai School of Medicine; N=2, 
n=0), Mark Molitch (Northwestern University; N=2, n=2), Pamela Freda (Columbia 
University Medical Center – New York Presbyterian; N=2, n=0), Adriana 
Ioachimescu (Emory University School of Medicine/Winship Cancer Institute; N=1, 
n=0), Peter Snyder (University of Pennsylvania – Clinical Studies Unit; N=1, n=1), 
Richard Auchus (University of Michigan; N=5, n=2), Roberto Salvatori (The Johns 
Hopkins University School of Medicine; N=1, n=0), Janice Kerr (University of 
Colorado Hospital; N=1, n=0), Eliza Geer and Monica Girotra (Memorial Sloan 
Kettering Cancer Cancer; N=1, n=0). 
Co-investigators: Argentina: Carolina Ballarino, Javier Farias; Austria: Castillo 
Jacqueline, Greisa Vila, Michaela Riedl, Michael Leutner; Bulgaria: Yuliya Nedelcheva, 
Atanaska Elenkova, Ivayla Uzunova, Emiliya Simeonova-Dimitrova, Zhivka Tsotova; 
Canada: Jean-Patrice Baillargeon, Diego Bellabarba, Patrice Perron, André Carpentier, 
 43 
Marie-Helene Pesant, Nicole Van Rossum, Frederic Bernier, Marie-France Langlois, Isabelle 
Bourdeau, Jean-Louis Chiasson, Churn-Ern Yip, Barna Tugwell, Thomas Ransom, Stephanie 
Kaiser, Andrea Opgenorth; China: Xiaojuan Wu, Lian Duan, Jiaqi Li, Nan Yu; Colombia: 
Adriana Serrano; France: Anne-Cecile Paepegaey, Seray Genc, Catherine Cormier, Assie 
Guillaume, Abdallah Al-Salameh, Laurent Becquemont, Jerry Blustajn, Imane Anajjar, 
Marie-Laure Nunes, Amandine Ferriere, Emilie Pupier, Magali Haissaguerre, Marie Marty, 
Jean-Benoit Corcuff, Vincent Tintignac, Frederique Albarel-Loy, Frederic Castinetti, Claire 
Rochette, Nadine Girard, Isabelle Morange, Attye Arnaud, Caroline Dubois, Christine Cortet, 
Georges Lion, Gustavo Soto Ares, Maria Claire Migaud; Germany: Robert Kosilek, Sylvère 
Stoermann, Anastasia Athanasoulia-Kaspar, Katharina Schilbach, Tanja Bergmann, Rosina 
Riel, Jens Aberle, Rudolf Oeverink, Gabreile Wenzel, Julia Domberg; India: Felix 
Jebasingh, Riddhi Gupta, Nihal Thomas, Mathews Kurian, Samantha S, Chaithanya Murthy, 
Kripa Cherian, Kaushiki Kirti, Vinay Kumar, Mala Dharmalingam, Anil Bhansali, Vivek 
Gupta, Rajesh Vijay Vargiya, Devasenathipathy Kandasamy, Nikhil Tandon; Italy: Elisa 
Verrua, Massimo Fabio Ulivieri, Federico Lombardi, Eriselda Profka, Elena Malchiodi, Elisa 
Sala, Marcello Filopanti, Laura Luigia Affinito Bonabello, Miryam Talco, Alberto Rebora, 
Elena Nazzari, Andrea Casabella, Lara Castelletti, Federico Gatto, Massimo Casu, Claudia 
Campana, Marialuisa Zilio, Carla Scaroni, Nora Elvira Albiger, Filippo Ceccato, Mattia 
Barbot, Valentina Camozzi, Francesco Causin, Cristino Sarais, Grazia Michetti, Marianna 
Martino, Giorgia Marcelli, Maria Cristina De Martino, Davide Iacuaniello, Monica De Leo, 
Chiara Simeoli, Fabio Tortora, Marialuisa Di Cera, Erika Messina, Oana Ruxandra Cotta, 
Maria Luisa Torre, Francesca Granata, Soraya Puglisi, Luca Manetti, Isabella Lupi, 
Vitantonio Di Bello, Mirco Cosottini, Claudio Marcocci; Japan: Toshiki Nozaki, Kenichi 
Oyama, Tadashi Higuchi, Yutaka Igarashi, Yujiro Hattori, Shunsuke Nakagawa, Eitaro 
Ishisaka, Hirotomo Ten, Makoto Ujihara, Hirofumi Hara, Yu Tsutsumi, Kenshi Kan, Takashi 
Miwa, Shinichi Tamaru, Rokuro Ito, Tomono Takahashi, Ketchu Yanagi, Takaaki 
Kobayashi, Takashi Tanabe, Junpei Shikuma, Masasuke Ohno, Takayuki Awaya, Takuma 
Miyazawa, Mizuka Ikezawa, Kazunori Shintai, Takahiro Oyama, Tatsuo Takahashi, Takumi 
Asai, Kinya Yokoyama, Hirokazu Okazaki, Manabu Kadoya, Yuji Moriwaki, Mariko Naka, 
Miki Kakutani, Masafumi Kurajo, Takuhito Shoji, Akiko Morimoto, Kae Hamamoto, Akio 
Miyoshi, Mayu Takahashi, Keiko Kitajima, Keizo Onaka, Shunsuke Katsuhara, Shohei 
Sakamoto, Hidenori Fukuoka, Genzo Iguchi; Korea: Chansoo Shin, JiHyun Lee, Seongyeon 
Kim, Yeseul Yang, Sehee Min, Jieun Jun, Cheolryong Ku, Wonjin Kim, Sehee Park, 
 44 
Wookyung Lee; Netherlands: J (H) Hofland; Russia: Alexandra Shishkina, Natalia 
Gragunova, Elizaveta Mamedova, Patimat Khandaeva, Ekaterina Pigarova, Liudmila 
Rozhinskaya, Alferova Polina, Tatyana Chernova, Svetlana Arapova, Larisa Dz Eranova, 
Alexander Lutsenko; Spain: Elena Dios Fuentes, Pilar Maiquez Asuero, Eva Venegas 
Moreno, Alberto Borobia, Hoi Tong, Monica Coronado, Maria Arnoriaga Rodriguez, Juan 
Carlos Percovich, Yoko Lucia Olmedilla Ishishi, Laura Ramirez; Thailand: Padiporn 
Limumpornpetch, Noppadol Kietsiriroje, Nuttha Sanghan; Turkey: Fatma Keskin, Ozge 
Polat Korkmaz, Ozlem Haliloglu; United Kingdom: Claire Higham, Alia Munir, Eleni 
Daniel, Nayananjani Karunasena, David Collier, Manish Sexena; United States: Elena 
Varlamov, Dara Ono, Sarah Hopkins, Justin Cetas, Christine Yedinak, Shao Ting Dawn Lim, 
Ty Carroll, Bradley Javorsky, Yelena Lalazar, Nirali Shah, Khadeen Cheeseman, Akexandria 
Atuahene, Wenyu Huang, Amisha Wallia, Adriana Kuker, Priya Dayamani, Julia Kharlip, 
Ariel Barkan, Tobias Else, Adina Turcu, Nestoras Mathioudakis, Katja Kiseljak-Vassiliades, 






















Tumour volume assessment 
Pituitary magnetic resonance imaging (MRI) with gadolinium enhancement (unless 
contraindicated) was performed at each study site according to standardised image 
acquisition guidelines and the images assessed centrally. If MRI could not be 
conducted, then computed tomography (CT) of the pituitary was performed. The 
modality of imaging remained consistent to that used at baseline unless a 
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contraindication developed. The readings were performed by an independent review 
committee of neuroradiologists who were blinded to randomised treatment and the 
time point at which the image was taken. The outer boundaries of the pituitary 
tumour/gland (region of interest) were semi-automatically delineated using the post-
contrast T1 MRI sequence (preferred) or post-contrast coronal reconstruction CT 
images, as applicable. The total combined volume of pituitary tumour/gland was 
automatically calculated by adding the measured cross-sectional areas and the slice 
thickness. The percentage change in volume at each follow-up time point relative to 
baseline was automatically calculated and recorded in the background but not 
displayed to the neuroradiologist. 
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Supplementary Table 1. Summary of reference ranges 
Parameter Units Gender Age, 
years 
Reference range 
Urinary free cortisol nmol/24h Male and female ≥18 11–138 
Testosterone nmol/L Male ≥18 8·36–28·67 
  Female ≥18 0·69–2·63 
Plasma ACTH pmol/L Male ≥18 1·6–11·1 (7–10 am) 
  Female ≥18 1·1–6·0 (7–10 am) 
Early-morning serum cortisol nmol/L Male and female ≥18 127–567 
Serum 11-deoxycortisol nmol/L Male 18–29 ≤3·45 
  Male 30–39 ≤3·92 
  Male 40–49 ≤2·2 
  Male 50–59 ≤1·22 
  Female 18–29 ≤3·1 
  Female 30–39 ≤1·48 
  Female 40–49 ≤1·8 
  Female 50–59 ≤1·07 
Late-night salivary cortisol nmol/L Male and female ≥18 ≤2·5 (10–11 pm) 
Plasma aldosterone pmol/L Male and female ≥18 ≤777 (upright  
8–10 am) 
≤583 (upright  
4–6 pm) 




µmol/L Male 18–21 0·7–14·6 
  Male 22–30 2·3–18·8 
  Male 31–40 2·9–12·6 
  Male 41–50 1·9–13·5 
  Male 51–60 1·0–8·5 
  Male 61–70 0·7–6·6 
  Male ≥71 0·1–6·9 
  Female 18–21 1·4–8·7 
  Female 22–30 0·5–10·6 
  Female 31–40 0·6–7·2 
  Female 41–50 0·5–6·3 
  Female 51–60 0·2–5·1 
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  Female 61–70 0·3–3·6 
  Female ≥71 0·2–4·8 
11-deoxycorticosterone pmol/L Male ≥18 ≤455 
  Female ≥18 ≤545 (mid-follicular) 
≤696 (surge) 
≤575 (mid-luteal) 
Renin µIU/L Male and female ≥18 4·4–46·1 
Serum oestradiol pmol/L Male ≥18 ≤106 







Oestrone pmol/L Male ≥18 ≤255 






ACTH, adrenocorticotropic hormone 
 48 
Supplementary Table 2. Proportion of mUFC responders at time points up to 
week 48, overall and by randomised treatment group 
 Treatment during randomised withdrawal 
phase 
 


















































































































All responders = complete + partial responders; complete responder = mUFC ≤ULN; partial 
responder = mUFC >ULN but >50% reduction from baseline. mUFC, mean urinary free cortisol; 
ULN, upper limit of normal 
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Supplementary Table 3. Change from baseline in clinical signs and features of 
hypercortisolism at week 48 in all patients 








baseline (95% CI) 
Mean percentage 
change from baseline 
(95% CI) 
Weight, kg 80·8 (22·4) 75·5 (20·7) –3·8 (–4·8, –2·7) –4·6 (–5·8, –3·3) 
BMI, kg/m2 30·3 (7·8) 28·4 (7·1) –1·4 (–1·8, –1·0) –4·6 (–5·8, –3·3) 
Systolic blood 
pressure, mmHg 
132·2 (15·1) 121·7 
(13·7) 
–9·8 (–12·7, –6·9) –6·8 (–8·9, –4·7) 
Diastolic blood 
pressure, mmHg 
85·3 (10·6) 78·9 (10·1) –6·3 (–8·4, –4·2) –6·6 (–9·0, –4·2) 
Fasting plasma 
glucose, mg/dL 
99·2 (29·8) 87·2 (18·9) –9·5 (–14·3, –4·8) –7·1 (–10·4, –3·8) 
HbA1c, % 6·0 (1·0) 5·6 (0·8) –0·4 (–0·5, –0·2) –5·4 (–7·2, –3·6) 
Total cholesterol, 
mmol/L 
5·3 (1·2) 4·8 (1·0) –0·5 (–0·7, –0·3) –8·8 (–11·8, –5·8) 
LDL cholesterol, 
mmol/L 
3·0 (1·0) 2·8 (1·0) –0·2 (–0·4, –0·1) –5·4 (–10·4, –0·4) 
HDL cholesterol, 
mmol/L 
1·6 (0·5) 1·3 (0·3) –0·3 (–0·3, –0·2) –14·4 (–17·5, –11·4) 
Triglycerides, 
mmol/L 
1·5 (1·3) 1·4 (0·9) –0·1 (–0·2, 0·1) 5·4 (–14·0, 24·9) 
CushingQoL score 42·2 (19·1) 58·3 (21·3) 14·1 (10·9, 17·3) 52·4 (32·2, 72·7) 
BDI score 16·8 (10·6) 10·7 (10·7) –5·8 (–7·6, –4·1) –31·8 (–44·3, –19·3) 
Reference ranges: plasma glucose 70–125 mg/dL; HbA1c ≤6·4%; total cholesterol 0–5·2 mmol/L; 
HDL cholesterol >0·89 mmol/L; LDL cholesterol 0–3·4 mmol/L; triglycerides 0–2·2 mmol/L. BDI, 
Beck’s Depression Inventory; BMI, body mass index; CushingQoL, Cushing’s Quality-of-Life 
Questionnaire; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; SD, standard deviation 
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Supplementary Table 4. Percentage change from baseline in cardiovascular­
related metabolic parameters associated with Cushing’s disease at selected 
visits during the core period, in all patients 
 Mean value at 
baseline (SD) 
Mean percentage change from baseline (95% CI) 
Parameter Week 12 Week 24 Week 48 
Weight, kg 80·8 (22·4) –0·9 (‒1·6, ‒0·2) –3·0 (‒3·9, ‒2·1) –4·6 (–5·8, –3·3) 
Body mass index, 
kg/m2 
30·3 (7·8) –0·9 (‒1·6, ‒0·2) –3·0 (‒3·9, ‒2·1) –4·6 (–5·8, –3·3) 
Systolic blood 
pressure, mmHg 
132·2 (15·1) –4·8 (‒7·0, ‒2·6) –4·1 (‒6·2, ‒2·0) –6·8 (–8·9, –4·7) 
Diastolic blood 
pressure, mmHg 
85·3 (10·6) –4·7 (‒7·0, ‒2·5) –3·8 (‒6·2, ‒1·4) –6·6 (–9·0, –4·2) 
Fasting plasma 
glucose, mg/dL 
99·2 (29·8) –7·0 (‒10·4, ‒3·6) –10·0 (‒13·0, ‒7·1) –7·1 (–10·4, –3·8) 
HbA1c, % 6·0 (1·0) –5·0 (‒6·4, ‒3·5) –4·6 (‒6·2, ‒3·0) –5·4 (–7·2, –3·6) 
Total cholesterol, 
mmol/L 
5·3 (1·2) –8·9 (‒11·8, ‒6·0) –9·0 (‒12·1, ‒6·0) –8·8 (–11·8, –5·8) 
LDL cholesterol, 
mmol/L 
3·0 (1·0) –5·0 (‒10·0, 0·0) –3·5 (‒9·0, 2·0) –5·4 (–10·4, –0·4) 
HDL cholesterol, 
mmol/L 
1·6 (0·5) –19·9 (‒22·8, ‒16·9) –14·3 (‒17·0, ‒11·6) –14·4 (–17·5, –11·4) 
Triglycerides, 
mmol/L 
1·5 (1·3) 15·2 (5·6, 24·8) –1·8 (‒8·1, 4·5) 5·4 (–14·0, 24·9) 
CushingQoL 
score 
42·2 (19·1) 29·1 (18·8, 39·5) 42·4 (23·5, 61·4) 52·4 (32·2, 72·7) 
BDI score 16·8 (10·6) –14·5 (–28·4, –0·5) –19·2 (–31·8, –6·5) –31·8 (–44·3, –19·3) 
Normal ranges: plasma glucose 70–115 mg/dL; HbA1c ≤6·4%; total cholesterol ≤5·2 mmol/L; HDL 




Supplementary Table 5. Summary of adverse events in all patients (all grades 
and grade 3/4)  
All patients All grades, n (%) Grade 3/4, n (%) 
Summary of AEs   
Any AE 137 (100) 78 (56·9) 
Any serious AE 50 (36·5) 39 (28·5) 
AEs requiring dose 
interruption and/or change 
106 (77·4) 39 (28·5) 
Death 1 (0·7) 1 (0·7) 
Most common study emergent AEs (occurring in >15% of patients overall) 
Nausea 57 (41·6) 3 (2·2) 
Headache 46 (33·6) 4 (2·9) 
Fatigue 39 (28·5) 3 (2·2) 
Adrenal insufficiency* 38 (27·7) 6 (4·4) 
Nasopharyngitis 31 (22·6) 1 (0·7) 
Vomiting 30 (21·9) 4 (2·9) 
Glucocorticoid deficiency† 29 (21·2) 5 (3·6) 
Arthralgia 27 (19·7) 3 (2·2) 
Back pain 27 (19·7) 0 (0) 
Diarrhoea 25 (18·2) 1 (0·7) 
Influenza 24 (17·5) 0 (0) 
Asthenia 23 (16·8) 1 (0·7) 
Blood ACTH increased 23 (16·8) 1 (0·7) 
Oedema peripheral 21 (15·3) 0 (0) 
Anticipated AEs of special interest 
Adrenal hormone precursor 
accumulation related 
58 (42·3) 22 (16·1) 
Hypocortisolism related 70 (51·1) 14 (10·2) 
Pituitary tumour enlargement 
related 
3 (2·2) 0 
QT prolongation related 5 (3·6) 1 (0·7) 
Arrythmogenic potential 1 (0·7) 1 (0·7) 
Patients with multiple events in the same category are counted only once in that category. 
*Adrenal insufficiency includes ‘relative adrenal insufficiency’, ‘adrenocortical insufficiency’, 
‘hypoadrenalcorticism’, ‘suspected hypoadrenalism’, ‘mild adrenal insufficiency’, and ‘adrenal 
deficiency’; †Glucocorticoid deficiency includes ‘hypocortisolism’, ‘symptoms of hypocortisolism’, 
‘relative hypocortisolism’, ‘suspicion of hypocortisolism’, ‘asymptomatic/symptomatic 
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hypocortisolism’, and ‘subjective symptoms of hypocortisolism’; clinical signs and serum cortisol 
measurements were not systematically collected. AE, adverse event 
 
Supplementary Table 6. Pairwise correlation between ACTH (pmol/L) and 
mUFC (nmol/24h) over time in all patients 
n Pearson’s correlation, r 
Baseline 137 0.56 
Week 12 124 0.10 
Week 24 124 0.12 
Week 48 108 –0.10 
 
Supplementary Figure 1. Intrapatient changes in mUFC levels during the 
randomised withdrawal period for patients randomised to a) osilodrostat and 






Supplementary Figure 2. Mean a) mUFC, b) serum cortisol, c) morning salivary 
cortisol, and d) late­night salivary cortisol at time points up to week 48, overall 
and by randomised treatment group  
 
Includes scheduled visits only. Shaded areas indicate the randomised withdrawal period, starting 
at week 26 and ending at week 34. Normal ranges are as follows: UFC, 11–138 nmol/24h; serum 
cortisol, 127–567 nmol/L; morning salivary cortisol, 1·1–15·5 nmol/L; late-night salivary cortisol, 
≤2·5 nmol/L. *For patients randomised to placebo during the randomised withdrawal period and 
including all data while on either treatment (ie including data for patients who were randomised to 
placebo but restarted open-label osilodrostat before the end of the randomised withdrawal period) 
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Supplementary Figure 3. Scatter plot of plasma osilodrostat Cmax versus 
change in serum potassium from baseline up to data cut­off 
 
Intercept = 0·1425; estimate (95% CI) for Cmax = –0·0036 (–0·0044, –0·0028). Cmax, maximum 
plasma concentration 
 
Supplementary Figure 4. Mean plasma ACTH levels at time points up to week 
48 by treatment group  
 
ACTH was assessed using the Immulite 2000 ACTH kit; ULN = 11·1 pmol/L (males), 6·0 pmol/L 
(females). *For patients randomised to placebo during the randomised withdrawal period and 
including all data while on either osilodrostat or placebo. Shaded areas indicate the randomised 
withdrawal period, starting at week 26 and ending at week 34 
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Supplementary Figure 5. Mean plasma 11­deoxycortisol levels at time points 
up to week 48, by treatment group, in a) males and b) females  
 
*For patients randomised to placebo during the randomised withdrawal period and including all 
data while on either osilodrostat or placebo. Shaded areas indicate the randomised withdrawal 




Supplementary Figure 6. Mean serum testosterone levels at time points up to 
week 48, by treatment group, in a) males and b) females  
 
Testosterone reference range: 8.4–28·7 nmol/L (males), 0.7–2·6 nmol/L (females). *For patients 
randomised to placebo during the randomised withdrawal period and including all data while on 
either osilodrostat or placebo. Shaded areas indicate the randomised withdrawal period, starting 
at week 26 and ending at week 34. LLN, lower limit of normal 
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Supplementary Figure 7. Mean hormone levels at time points up to week 48 by 
treatment group for a) plasma aldosterone, b) serum dehydroepiandrosterone 
sulphate (DHEAS), c) serum 11­deoxycorticosterone, d) plasma renin, e) serum 
oestradiol, and f) serum oestrone  
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Shaded areas indicate the randomised withdrawal period, starting at week 26 and ending at 
week 34. 
 
